Incontinence & Overactive Bladder Health Center
References
Citations
Lentz GM (2007). Physiology of micturition, diagnosis of voiding dysfunction, and incontinence: Surgical and nonsurgical treatment. In VL Katz et al., eds., Comprehensive Gynecology, 5th ed., pp. 537–568. Philadelphia: Mosby Elsevier.
American College of Obstetricians and Gynecologists (2005, reaffirmed 2007). Urinary incontinence in women. ACOG Practice Bulletin No. 63. Obstetrics and Gynecology, 105(6): 1533–1545.
Sutherland SE, Goldman HB (2004). Treatment options for female urinary incontinence. Medical Clinics of North America, 88(2): 345–366.
Norton P, Brubaker L (2006). Urinary incontinence in women. Lancet, 367: 57–67.
Keegan PE, et al. (2007). Periurethral injection therapy for urinary incontinence in women. Cochrane Database of Systematic Reviews (3).
Onwude J (2007). Stress incontinence, search date December 2006. Online version of BMJ Clinical Evidence. Also available online: http://www.clinicalevidence.com.
Hendrix SL, et al. (2005). Effects of estrogen with and without progestin on urinary incontinence. JAMA, 293(8): 935–948.
Grady D, et al. (2001). Postmenopausal hormones and incontinence: The Heart and Estrogen/Progestin Replacement Study. Obstetrics and Gynecology, 97(1): 1116–1120.
Emmons SL, Otto L (2005). Acupuncture for overactive bladder. Obstetrics and Gynecology, 106(1): 138–143.
Holroyd-Leduc JM, Straus SE (2004). Management of urinary incontinence in women. JAMA, 291(8): 986–995.
Other Works Consulted
Barber MD, et al. (2008). Transobturator tape compared with tension-free vaginal tape for the treatment of stress urinary incontinence. Obstetrics and Gynecology, 111(3): 611–621.
Tanagho EA, et al. (2008). Urinary incontinence. In EA Tanagho, JW McAninch, eds., Smith's General Urology, 17th ed., pp. 473–489. New York: McGraw-Hill Medical.
WebMD Medical Reference from Healthwise
Urinary Incontinence Women's Guide
Important Safety Information
Do not take UROXATRAL if you have liver problems or if you are taking antifungal drugs like ketoconazole or itraconazole, or HIV drugs like ritonavir.
UROXATRAL can cause a sudden drop in blood pressure, especially when starting treatment. This may lead to fainting, dizziness, and lightheadedness. Do not drive, operate machinery, or do any dangerous activity until you know how UROXATRAL will affect you. This is especially important if you already have a problem with low blood pressure or take medicines to treat high blood pressure. There may be an increased risk of low blood pressure and fainting when taking UROXATRAL in combination with blood pressure medication or nitrates, or erectile dysfunction medication.
If considering cataract surgery (clouding of the eyes), tell your eye surgeon that you are currently taking UROXATRAL or have previously been treated with an alpha-blocker.
Before taking UROXATRAL, tell your doctor if you have kidney problems.
Also, tell your doctor if you or any family member(s) have or take medications for a rare heart condition known as congenital prolongation of the QT interval.
BPH and prostate cancer can cause the same symptoms. However, UROXATRAL is not a treatment for prostate cancer.
The most common side effects with UROXATRAL are dizziness, upper respiratory tract infection, headache, and tiredness.
Indication
Uroxatral® (alfuzosin HCl 10 mg extended-release tablets) is an alpha1-blocker for the treatment of the signs and symptoms of BPH.
Please see UROXATRAL full prescribing information.
